Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).

Esteban JódarMarie MichelsenWilliam PolonskyRosangela RéaAnna SandbergTina Vilsbøll Mark L WarrenSigne HarringUwe ZieglerStephen C Bain

Published in: Diabetes, obesity & metabolism (2020)

Semaglutide improved HRQoL versus placebo; greater improvements with semaglutide versus placebo were possibly mediated, in part, by change in HbA1c and body weight. Clinicaltrials.gov: NCT01720446 (SUSTAIN 6).

Keyphrases

body weight
double blind
palliative care
phase iii
randomized controlled trial
quality improvement
placebo controlled
pain management